Scancell Share Discussion Threads

[tosh123] 13/9/2017 12:13

As can be seen from ALL the content of the RNS, and indeed the Proactive article, the funding ISSUE, is still very much NOT sorted.... its there in black and white.
The preferred route to funding is after the securing of one or more partnerships, which in turn, as per the words from the horses mouth, Scancell are " still on the lookout for ".
Far from being sorted in any way what so ever, it would appear that the ISSUE is still very much alive and kicking.
The clock, once again, is now ticking. Cash in the bank will last about another 12 months, probably less, as once the cash reduces to a certain amount ( not zero, or anywhere near zero ) they will need to raise yet more money to pay the bills, yet again, until a deal is sorted.
The risks are there for everyone to see, and always have been.... Ladies and gentlemen, place your bets.

[inanaco] 13/9/2017 11:54

Clearly funding is not an issue,

We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase and the Board believes that this funding could be best achieved following the execution of one or more partnerships on the ImmunoBody® or Moditope® platforms, on which significant progress has been made since the year end."

Its now up to you guys to decide to buy and hold and wait the deal,(most likely outcome) which is exactly what i have been posting ..

Nobody knows when ....... no point in blowing Hot Air if you miss the balloon ride

Gazza i guess Scancell has now used the words "efficient"

[tosh123] 13/9/2017 11:48

This headline from today's article in Proactive Investor, speaks volumes.

Scancell on the lookout for partners after year of “significant progress”

Note the words " on the lookout ".... That scares me, and sort of reinforces my belief that there are not currently any deals on the table.

[drdobson] 13/9/2017 10:46

Loz.Right as usual and seems Nana Ludd has gone to ground TRYing to hyPE his response to FUNDING ISSUE which is NOT an ISSUE but WHY is share price down?

[rhatton] 13/9/2017 10:29

Tosh agreed. This really is crunch time. Most of my 'hope' if you will is with moditope. That seems truly ground breaking technology. So hopefully some thing comes with that.

But absolutely agree that we've heard it all before.

[kreature] 13/9/2017 10:28

if this were so good where is the next phase of the scib trial?

[the real lozan] 13/9/2017 10:14

The other day -Gash 'pressed' me to "Make a comment about SCLP { in English}
I replied with one word = " FUNDING " ???
{ IN hopes the the 'more intelligent' WOULD 'see the point'... some may have ... BUT... the 'louds' appeared not to }
It seems today, however, each and everyone is focused on the = "FUNDING" question, which I pointed-out { and as usual was 'pilloried' for - by the unreliables}
WAS and IS 'paramount.
But, there you go
.
*WE* have been repeatedly 'brow-beaten' into being led down the path of the "Our SCIENCE is number ONE","The SCIENCE will see us through", "He won't talk about the SCIENCE" anon anon. = ALL misleading trHYPE.
Leading the 'sheeple' to CON centrate on the WRONG SCIENCE
.
There is the "Theoretical SCIENCE" = To come-up with the 'IDEA' - experiment ETC. -which costs / NEEDS 'little FUNDING'
Then there is the 'next stage' I have been trying to 'high-light' =
The "Practical SCIENCE", where one NEEDS to PROVE the original 'IDEA' - WORKS
A much more different BIGGER 'kettle-of-fish'... Which costs /NEEDS a GREAT DEAL OF FUNDING.
Which, it appears SCLP are at/ entering that stage
.
The question one should FOCUS on... is WHERE will that FUNDING come from ??? and WHAT will that FUNDING = COST

[tosh123] 13/9/2017 10:12

rH,
i agree with you, but the problem ( from my prospective ) is that we have heard words used that are far more positive than " hopeful " many times before, with regards to prospective deals, only for absolutely nothing to materialise, so all credibility has been lost, and thats a problem.
The company CEO, has to have credibility, its crucial, but i dont think i'm alone in saying that he has zero left, from where im standing.

[rhatton] 13/9/2017 09:54

Tosh, it looks more like they are hopeful of a deal on moditope that r SCIB2 to raise the share price and then make funding easier from a dilution perspective. The word 'hopeful' being key. One more year to go and if nothing then it's going to be another fund raising to keep the lights on whilst they / we keep hoping.
As you say though, one deal and sentiment and prospects change immediately

[tosh123] 13/9/2017 09:52

P... i couldn't agree more, like i said, the standard of management stinks .
Some small voices can't change that situation though, we need the II's to start bulking.
I cant think of any other company that has such massive potential for riches, yet has been managed quite so badly, it astounds me ... Ive said it before and i'll say it again, i feel for LD, her work has not received the support internally that it merits... We are lucky to still have her.

Forget about any of the so called " scientific experts " on certain BB's, this is Lindy's creation, her science, she is the one with all the knowledge, not a jumped up midget who professes to be all knowing.
In Lindy i trust.... If she wasn't there, then nor would i be.
RG has ridden on her shirt tails for long enough, time to get rid, IMHO.

[panama7] 13/9/2017 09:38

Tosh, we have been consistently told for the last 5 years that there is significant interest in both platforms, yet Goodfellow the Commercial CEO has failed to deliver anything of substance for Shareholders.

[kreature] 13/9/2017 09:37

Oh dear, where did the money go?

[tosh123] 13/9/2017 09:32

Unfortunately, the main " financial " issue, still remains.
As MTB says, a good product, but that promise is not reflected by the standard of management.... in fact, to be honest, it stinks !
There are still massive risks here until a deal is done, get that first one over the line and sentiment will change straight away ( subject to the terms of any such deal, obviously ).
My hope is that there are genuine prospects of a deal / deals, subject to certain criteria being met, eg an agreement in principle has already been secured, but the terminology of the RNS, doesn't suggest that to be the case.
If nothing changes between now and the AGM, i would envisage a very heated meeting.

Lets just hope that there is something in the bin already, and its just that they cant tell us about it yet.
fingers crossed.

[panama7] 13/9/2017 09:24

Terror, spot on and don't forget Goodfellow's tweet of 2 years ago " FUNDING IS EASY WHEN YOU HAVE A SUCCESSFUL PHASE11 BEHIND YOU ". The bloke is a complete waste of space zero credibility, integrity and honesty. He has to go.

[mikethebike4] 13/9/2017 09:06

Terror

I agree - good product but always funding issues - very disappointing after all this time

[tosh123] 13/9/2017 08:53

Terror,
couldn't agree more, and have said so for many years now.

[terror] 13/9/2017 08:25

The old funding issue raises its head again and the share price reacts to a Company short on cash, struggling to get a deal done and further delays to the timetable.

Goodfellow has been and is a disaster. The Astute are well aware of the need to have a strategy that is fully funded, not a game plan that is made up as it goes along.

Goodfellow has no credibility.

[bermudashorts] 13/9/2017 07:45

Most importantly no patients have died and none have progressed since last update.

[skinny] 13/9/2017 07:16

Highlights:

· Strong survival data for patients with Stage III/IV malignant melanoma on SCIB1 Phase 1/2 clinical trial
o 18 of 20 patients with resected disease remain alive, survival well beyond established norms
o Of the 16 resected patients who received a 2-4mg dose of SCIB1, seven patients have now survived for five years since starting treatment and only six patients have had recurrence of their disease, of whom, two have died
o Final Clinical Study Report completed in December 2016 which included safety, immunology and clinical data from patients with Stage III/IV melanoma up to 29 October 2015

· Investigational New Drug (IND) application for SCIB1 Phase 2 checkpoint inhibitor combination study expected to be submitted in early 2018, with patient enrolment planned for 2018

· Continued good progress in development of Modi-1, our lead product from the Moditope® platform
o Ultra-efficient linked adjuvant identified that works at up to 100-fold lower doses than could be achieved previously
o Aiming to file a Clinical Trial Application (CTA) in the UK for the planned Phase 1/2 clinical trial in breast cancer, ovarian cancer and sarcoma in 2018
o Early feedback from the European Patent Office suggests that broad patent claims for the Moditope® platform may be allowable

· Opening of new offices in San Diego to support the Company's US growth plans, and in Oxford for its UK corporate and development activities

· Loss for year of £3.5m (2016: loss £2.6m)

· Group cash balance at 30 April 2017 was £2.7m (30 April 2016: £6.5m)

Post Period Highlights:

· Raised £4.7m in a placing of new ordinary shares
o Funds to be used to initiate the clinical development of Modi-1 and to continue to support the ImmunoBody® platform pipeline

· Patent granted in Europe for Scancell's DNA ImmunoBody® technology
o Counterparts to this patent have already been granted in the US, Australia and Japan

Dr Richard Goodfellow, CEO of Scancell, said:

"We have made further significant progress during the course of the past year on the development of our ImmunoBody® and Moditope® platforms. We continue to report strong survival data in patients with Stage III/IV melanoma from our SCIB1 Phase 1/2 clinical trial, with survival times now exceeding five years in resected patients.

Moditope® is also progressing well with the identification of a new linked adjuvant for the first Modi-1 clinical trial in the UK in patients with breast cancer, ovarian cancer and sarcoma which is expected to increase the potency of the product up to 100-fold.

We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase and the Board believes that this funding could be best achieved following the execution of one or more partnerships on the ImmunoBody® or Moditope® platforms, on which significant progress has been made since the year end."

[gazza] 13/9/2017 07:12

Results are out. A lot in there to digest, show that a lot has been happening behind the scenes.

[bermudashorts] 12/9/2017 21:18

"who seeks to exploit" - bit strong.

[drdobson] 12/9/2017 20:21

Loz Your 11527 I recommended as well and agree the 2 videos highlight the difference between you a man of substance and depth and the other one who is as shallow as a pancake.
I can't afford to have a 2nd home but appreciate the effort you have made to settle in France by immersing yourself in the local culture u like Nana who seeks to exploit the poor Thais.
We know how arrogant he is to people on here so can guess he looks down on the lovely Thai people.
Very pleased that you have done so well for yourself and appreciate your efforts to protect those amongst us that can't afford to lose our investment here from the LESS Scrupulous posters here

[panama7] 12/9/2017 18:09

Goosed, he also stated that the company would be transformed by the time of the next AGM. He also stated at the time of the 2016 fundraising that the money would enable the SCIB1 Combi trial to start in 2017. Like Goodfellow I would take his pronouncements with a pinch of salt.